[Statistical analysis on the postoperative survivals of cancer patients in the treatment of SSM (an extract from human tubercle bacilli, so called Maruyama vaccine)].
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D007564:Japan; D008055:Lipids; D008351:Mannans; D009369:Neoplasms / Q000401:mortality* / Q000628:therapy
D000970:Antineoplastic Agents; D001688:Biological Products; D008055:Lipids; D008351:Mannans; C031208:specific substance maruyama